Off-label reduced-dose apixaban does not reduce hemorrhagic risk in Taiwanese patients with nonvalvular atrial fibrillation A retrospective, observational study

doi:10.1097/MD.0000000000026272

Chia Nan University of Pharmacy & Science Institutional Repository > 藥理學院 > 藥學系(所) > 期刊論文 > Item 310902800/34408

請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34408

標題:	Off-label reduced-dose apixaban does not reduce hemorrhagic risk in Taiwanese patients with nonvalvular atrial fibrillation A retrospective, observational study
作者:	Chen, I-Chih Chang, Wei-Ting Hsu, Po-Chao Yeh, Ya-Lan Zheng, Syuan Huang, Yuan-Chi Lin, Chih-Hsien Tsai, Liang-Miin Lin, Li-Jen Liu, Ping-Yen Liu, Yen-Wen
貢獻者:	Tainan Municipal Hosp, Div Cardiol, Dept Internal Med Chia Nan Univ Pharm & Sci, Dept Pharm Chi Mei Med Ctr, Div Cardiol, Dept Internal Med Southern Taiwan Univ Sci & Technol, Dept Biotechnol Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Cardiol, Dept Internal Med Chang Gung Univ Sci & Technol, Chiayi Campus Natl Cheng Kung Univ Hosp, Dept Med Natl Cheng Kung Univ Hosp, Dept Internal Med, Div Cardiol Natl Cheng Kung Univ, Coll Med, Inst Clin Med
關鍵字:	direct oral anticoagulant nonvalvular atrial fibrillation off-label reduced-dose apixaban stroke
日期:	2021
上傳時間:	2023-11-11 11:50:20 (UTC+8)
出版者:	LIPPINCOTT WILLIAMS & WILKINS
摘要:	East Asians are reportedly at high risk of anticoagulant-related bleeding; therefore, some physicians prefer to prescribe low-dose direct oral anticoagulants (DOACs). Little is known about the therapeutic effectiveness and safety of off-label reduced-dose apixaban in East Asians with nonvalvular atrial fibrillation (AF). We aimed to investigate the effectiveness and safety of off-label reduced-dose apixaban in Taiwanese patients with nonvalvular AF. This retrospective cohort study enrolled 1073 patients with nonvalvular AF who took apixaban between July 2014 and October 2018 from 4 medical centers in southern Taiwan. The primary outcomes included thromboembolic events (stroke/transient ischemic attack or systemic embolism), major bleeding, and all-cause mortality. Among all patients, 826 (77%) patients were classified as the per-label adequate-dose treatment group (i.e., consistent with the Food and Drug Administration label recommendations) while 247 (23%) patients were the off-label reduced-dose treatment group. The mean follow-up period was 17.5 +/- 13 months. The off-label reduced-dose group did not have a lower major bleeding rate than the per-label adequate-dose group (4.8% vs 3.8%, adjusted hazard ratio [HR] 1.20, 95% confidence interval [CI] 0.69-2.09), but had a nonsignificantly higher incidence of thromboembolic events (4.23% vs 3.05%, adjusted HR: 1.29, 95% CI: 0.71-2.34). An off-label reduced-dose apixaban treatment strategy may not provide incremental benefits or safety for Taiwanese patients with nonvalvular AF.
關聯:	MEDICINE, v.100, n.23, e26272
顯示於類別:	[藥學系(所)] 期刊論文

文件中的檔案:

檔案	描述	大小	格式	瀏覽次數
index.html		0Kb	HTML	252	檢視/開啟
MD.0000000000026272.pdf		397Kb	Adobe PDF	53	檢視/開啟

在CNU IR中所有的資料項目都受到原著作權保護.

TAIR相關文章

資料載入中.....